The undesirable effects seen with hepatitis C are representative of those reported when IntronA is administered in other indications, with some anticipated dose-related increases in incidence.
Hepatiit C puhul täheldatavad kõrvaltoimed sarnanevad juhtudele, kus IntronA- d manustatakse teistsugustel näidustustel, kusjuures esineb oodatavat annusest sõltuvat esinemissageduse tõusu.